APGE APOGEE THERAPEUTICS INC

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences:

Jefferies Global Healthcare Conference

Date: Thursday, June 6, 2024

Time: 8:30 a.m. ET

Goldman Sachs 45th Annual Global Healthcare Conference

Date: Monday, June 10, 2024

Time: 11:20 a.m. ET

A live and archived webcast of the fireside chat and presentation will be available via the page in the Investors section of the Apogee Therapeutics website.

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit .

Investor Contact:

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics, Inc.

Media Contact:

Dan Budwick

1AB



EN
23/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOGEE THERAPEUTICS INC

 PRESS RELEASE

Apogee Therapeutics Expands Board of Directors with the Appointment of...

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company’s board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clin...

 PRESS RELEASE

Apogee Therapeutics to Participate in Upcoming June Investor Conferenc...

Apogee Therapeutics to Participate in Upcoming June Investor Conferences SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 6, 2024Time: 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare ConferenceDate: Mond...

 PRESS RELEASE

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis ...

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025 Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additi...

David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Apogee Therapeutics Highlights Pipeline Progress and Reports First Qua...

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data from Part A of the trial expected in 2H 2025 First participant dosed in Phase 1 healthy volunteer clinical trial of APG808, a subcutaneous half-life extended monoclonal antibody targeting IL-4Rα, for the treatment of chronic obstructive pulmonary disease and other inflammatory diseases with...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch